Fibronectin interaction with α4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: Correlation with Bcl-2 and Bax

Leukemia

Volumn 13, Issue 2, 1999, Pages 266-274

  De La Fuente, M T ^a   Casanova, B ^a   Garcia Gila, M ^a   Silva, A ^a   Garcia Pardo, A ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Apoptosis; B CLL; Bcl 2 Bax ratio; Fibronectin; 4 1 integrin

Indexed keywords

FIBRONECTIN; INTEGRIN; PROTEIN BAX; PROTEIN BCL 2; BAX PROTEIN, HUMAN; HOMING RECEPTOR; ONCOPROTEIN; TUMOR PROTEIN; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; B CELL LEUKEMIA; CELL CULTURE; CELL SURVIVAL; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL SURVIVAL; FEMALE; FIBRONECTINS; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRINS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, LYMPHOCYTE HOMING; TUMOR CELLS, CULTURED;

EID: 0032588618     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401275     Document Type: Article

References (44)

1. Freedman AS, Nadler LM. Immunologic markers in B-cell chronic lymphocytic leukaemia. In: Cheson BD (ed). Chronic Lymphocytic Leukaemia: Scientific Advances and Clinical Developments. Marcel Dekker: New York, 1992, pp 1-32.
2. Kroft SH, Finn WG, Peterson LC. The pathology of the chronic lymphoid leukaemias. Blood Rev 1995; 9: 234-250.
3. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JL, Kerr JFR. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989; 71: 343-350.
4. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-1326.
5. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon γ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177: 213-218.
6. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of Bcl-2 protein in B-chronic lymphocytic leukemia cells in vitro. Br J Haematol 1993; 85: 439-445.
7. Jewel AP. Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996; 21: 43-47.
8. Chaouchi N, Wallon C, Goujard C, Testian G, Rudent A, Caput D, Ferrera P, Minty A, Vázquez A, Delfiaissy JF. Interleukin-13 inhibits interleukin-2 induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 1996; 87: 1022-1029.
9. Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R. Interleukin 8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 1996; 15: 4382-4389.
10. Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. Inteleukin-6 inhibits apoptosis and tumor necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 1996; 22: 83-90.
11. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994: 76: 301-314.
12. De Rossi G, Zarcone D, Mauro F, Cerruti G, Tenca C, Puccetti A, Mandelli F, Grossi CE. Adhesion molecule expression on B-cell chronic lymphocytic leukemia cells: malignant cell phenotypes define distinct disease subsets. Blood 1993; 81: 2679-2687.
13. Takeuchi H, Katayama I. Surface phenotype and adhesion activity on B-cell chronic lymphoid leukemias. Leuk Lymphoma 1993; 10: 209-216.
14. Vincent AM, Cawley JC, Burthem J. Integrin function in chronic lymphocytic leukemia. Blood 1996; 87: 4780-4788.
15. Meredith JE, Schwartz MA. Integrin, adhesion and apoptosis. Trends in Cell Biol 1997; 7: 146-150.
16. Zhang A, Vuori K, Reed JC, Ruoslahti E. The α5β1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 1995; 92: 6161-6165.
17. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin αVβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
18. Anwar ARF, Moqbel R, Walsh GM, Kay AB, Wardlaw AJ. Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 1993; 177: 839-843.
19. Koopman G, Keehnen RMJ, Lindhout E, Newman W, Shimizu Y, van Seventer GA, de Groot C, Pals ST. Adhesion through the LFA-1-ICAM-1 and the VLA-4-VCAM-1 pathways prevents apoptosis of germinal center B cells. J Immunol 1994; 152: 3760-3767.
20. Panayiotidis P, Jone D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996; 92: 97-103.
21. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387-2396.
22. Long BW, Witte PL, Abraham GN, Gregory SA, Plate J. Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells. Proc Natl Acad Sci USA 1995; 92: 1416-1420.
23. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Ann Rev Immunol 1995; 13: 513-543.
24. Oltvai Z, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-192.
25. Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K, Caligaris-Cappio F. Growth and differentiation-associated of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992; 79: 2981-2989.
26. Hanada M, Delia D, Aiello A, Stadtmaner E, Reed JC. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820-1828.
27. Domínguez-Jiménez C, Sánchez-Aparicio P, Albar JP, Garcia-Pardo A. The α4β1 fibronectin ligands CS-1, Hep II and RGD induce different intracellular events in B lymphoid cells. Comparison with the effects of the endothelial ligand VCAM-1. Cell Adhes Comm 1996; 4: 251-267.
28. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
29. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 1989; 109: 1321-1330.
30. Mould AP, Askari JA, Craig SE, Garratt AN, Clements J, Humphries MJ. Integrin α4β1-mediated melanoma cell adhesion and migration on vascular cell adhesion molecule-1 (VCAM-1) and the alternatively spliced IICS region of fibronectin. J Biol Chem 1994; 269: 27224-27230.
31. Mould AP, Humphries MJ. Identification of a novel recognition sequence for the integrin α4β1 in the COOH-terminal heparin-binding domain of fibronectin. EMBO J 1991; 10: 4089-4095.
32. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 1989; 126: 271-279.
33. Garcia-Pardo A, Wayner EA, Carter WG, Ferreira OC. Human B lymphocytes define an alternative mechanism of adhesion to fibronectin: the interaction of the α4β1 integrin with the LHGPE-ILDVPST sequence of the type III connecting segment is sufficient to promote cell attachment. J Immunol 1990; 144: 3361-3366.
34. Arroyo AG, Garcia-Pardo A, Sánchez-Madrid F. A high affinity conformational state on VLA integrin heterodimers induced by an anti-β1 chain monoclonal antibody. J Biol Chem 1993; 268: 9863-9868.
35. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
36. Baldini L, Cro L, Calori R, Nobili L, Silvestris I, Maiolo AT. Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia. Blood 1992; 79: 2688-2693.
37. Eksioglu-Demiralp E, Alpdogan O, Aktan M, Firatli T, Ozturk A, Budak T, Bayik M, Akoglu T. Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. Leukemia 1996; 10: 1331-1339.
38. Mainou-Fowler T, Craig VA, Copplestone AJ, Hamon MD, Prentice AG. Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4. Blood 1994; 83: 2297-2304.
39. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996; 10: 456-459.
40. + B-cell apoptosis: co-incidence of cell death and DNA fragmentation with reduced bcl-2 expression. Br J Haematol 1996; 92: 950-953.
41. Osorio LM, De Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M. CD26 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 1997; 89: 2833-2841.
42. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of Bcl-2 and Bax. J Immunol 1996; 156: 2624-2630.
43. Thomas A, El Rouby S, Reed JC, Krajewsky S, Silber R, Potmesil M, Newcomb EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055-1062.
44. Pepper C, Hoy T, Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998; 28: 355-361.